Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of salbutamol monotherapy in slow-channel congenital myasthenic syndrome caused by a novel mutation in CHRND.

Muscle & nerve - 1 Apr 2021

Tawara Nozomu, Yamashita Satoshi, Takamatsu Koutaro, Yamasaki Yoshimune, Mukaino Akihiro, Nakane Shunya, Farshadyeganeh Paniz, Ohno Kinji, Ando Yukio

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Albuterol
Share to Mutation
Share to Myasthenic Syndromes, Congenital
Share to Neuromuscular Junction

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Receptors, Cholinergic

Source

Identifiers

PMID: 33428214
DOI: 10.1002/mus.27166

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of salbutamol monotherapy in slow-channel congenital myasthenic syndrome caused by a novel mutation in CHRND.PMID 33428214Read ↗

Slow channel congenital myasthenic syndrome responsive to a combination of fluoxetine and salbutamol.Semantic proximity Read ↗

Congenital myasthenia syndrome with demyelinating sensorimotor neuropathy responsive to salbutamol monotherapy: a novel clinical phenotype of CHRNE mutation.Semantic proximity Read ↗

DOK7 congenital myasthenic syndrome responsive to oral salbutamol.Semantic proximity Read ↗

Acetazolamide can improve symptoms and signs in ion channel-related congenital myopathy.Semantic proximity Read ↗

Quinine sulfate as a therapeutic option in a patient with slow channel congenital myasthenic syndrome.Semantic proximity Read ↗

Therapeutic strategies for congenital myasthenic syndromes.Semantic proximity Read ↗

Salbutamol-responsive limb-girdle congenital myasthenic syndrome due to a novel missense mutation and heteroallelic deletion in MUSK.Semantic proximity Read ↗

Mechanistic Diversity Underlying Fast Channel Congenital Myasthenic SyndromesSemantic proximity Read ↗

Clinical and neurophysiological response to ephedrine in a patient affected with slow-channel congenital myasthenic syndrome.Semantic proximity Read ↗

Nonlethal CHRNA1-Related Congenital Myasthenic Syndrome with a Homozygous Null Mutation.Semantic proximity Read ↗

A mouse model of the slow channel myasthenic syndrome: Neuromuscular physiology and effects of ephedrine treatment.Semantic proximity Read ↗

Treatment of slow-channel congenital myasthenic syndrome in a Thai family with fluoxetine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.